Hospital.Help

Baltimore – Patients with prostate cancer who experience biochemical signs of recurrence after surgery could benefit from treatment with the cancer drug olaparib without concomitant hormone therapy. This was the result of a study by the Johns Hopkins Kimmel Cancer Center and other institutions that was published in the journal JAMA Oncology (2024; DOI: 10.1001/jamaoncol.2024.3074). While most men with…